Nebivolol Stada (Nebivolol)

Nebivolol is a selective β1‑blocker used in cardiovascular therapy to manage blood pressure and cardiac performance.

• Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Heart failure with reduced ejection fraction: improves ventricular function and reduces hospitalisation risk.
• Elderly patients with hypertension: provides effective blood‑pressure control with a favorable tolerability profile.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, reducing heart rate and contractility. In addition, it stimulates endothelial nitric oxide synthase, leading to nitric‑oxide‑mediated vasodilation, which further contributes to blood‑pressure reduction without significant β2‑blockade.

Nebivolol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or general weakness.
• Nasal congestion or rhinorrhoea.
• Bradycardia: heart rate below normal resting levels.
• Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Symptomatic hypotension with risk of syncope.
• Acute heart failure decompensation.
• Allergic reactions such as rash, angio‑edema, or anaphylaxis.
• Hepatic enzyme elevation indicating possible liver injury.
• Depression or mood changes in susceptible individuals.

Before initiating Nebivolol, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal impairment: adjust therapy and monitor renal function.
• Hepatic impairment: use with caution; dose may need adjustment.
• Concomitant asthma or COPD: assess risk of bronchospasm.
• Pregnancy: safety not established; avoid unless benefit outweighs risk.
• Elderly patients: start at low dose and titrate slowly.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Nebivolol can interact with several drug classes; understanding the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

• Non‑selective beta‑blockers: additive β‑blockade may cause severe bradycardia.
• Calcium‑channel blockers verapamil or diltiazem: can increase plasma levels and risk of hypotension.
• Clonidine withdrawal: abrupt discontinuation may precipitate rebound hypertension.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance antihypertensive effect, requiring blood‑pressure monitoring.
• ACE inhibitors or ARBs: combined use can lead to additive blood‑pressure lowering.
• NSAIDs: may reduce antihypertensive efficacy and affect renal function.